Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascular Pharmacology · 2023-12 · 153 · 107238
DOI: 10.1016/j.vph.2023.107238 ↗Kurz gefasst
Editorial in der Zeitschrift Vascular Pharmacology, 2023-12. Verfasst von Paul M Ridker. Beteiligte Einrichtung: From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine and the Division of Cardiovascular Medicine, Brigham and Women…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Inflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Drug Administration to lower rates of myocardial infarction, stroke, and cardiovascular death as an adjunct to statin therapy. Physicians can anticipate novel anti-inflammatory agents in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine and the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: pridker@bwh.harvard.…
Zitieren
APA
Ridker, P. M. (2023). Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. Vascular Pharmacology, 153, 107238. https://doi.org/10.1016/j.vph.2023.107238
Vancouver
Ridker PM. Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. Vascular Pharmacology. 2023;153:107238. doi:10.1016/j.vph.2023.107238
BibTeX
@article{Ridker2023,
author = {Ridker, Paul M},
title = {Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention},
journal = {Vascular Pharmacology},
year = {2023},
volume = {153},
pages = {107238},
doi = {10.1016/j.vph.2023.107238}
}
EUVIMED